Anixa Biosciences Announces Abstract Accepted for Presentation at the 34th Annual Meeting of the...

Tailwinds' Take: With CLIA approval for Cchek in prostate cancer expected within weeks, Anixa is already moving forward on a second indication. The recent...

Anixa Biosciences Appoints Dr. Thomas Schlumpberger as Executive Vice President of Diagnostics to Head...

Tailwinds' Take: hiring an executive to lead business development is key for Cchek as Anixa will be looking to move the product onwards towards...

Anixa Biosciences Names Cancer Vaccine Pioneer Dr. Ian H. Frazer to Scientific Advisory Board

Tailwinds' Take: the key takeaway from this is that the top scientists in the world are now coming on board to work with Anixa....

Volatility Creating Opportunity…

I tend to be very much a buy and hold investor. I take positions, add to them as I gain confidence and generally let...

Anixa Biosciences Commences Collaboration with Potomac Urology Center on Cchek™ Prostate Cancer Study

Tailwinds' Take: endorsement from KOL's like the Potomac Urology Center is key to getting Cchek broad acceptance and a maximum valuation when they eventually...

An Interview With Anixa’s Dr. Amit Kumar

Now that the summer is over, and the fall conference season is ahead I thought it might be a good time for an interview...

Anixa Biosciences Congratulates Scientific Advisory Board Member Dr. H. Michael Shepard as a 2019...

Tailwinds' Take: The Lasker Award is a big honor and demonstrates the strength of Anixa's scientific board. Dr. Shepard's work in breast cancer has...

Fall Investor Preview Along With A Belated August Recap

I’ve held off on my August recap much like a war veteran will refrain from telling tales from the trenches. Not that my experiences...

LD Micro Recap

Today was the LD Micro SF Summit. As Chris Lahiji said, 27 companies, 27 investors. We all sit around the table and they bring...

If I Had A Nickel For Every Buying Opportunity…

The path to being a good investor is to be able to see what the future holds and place your bets accordingly. If you...

Anixa Biosciences Announces VA North Texas Health Care System to Join Cchek™ Prostate Cancer...

Tailwinds' Take: this is the third VA hospital to join the Cchek study. This demonstrates the success the diagnostic must be showing in other...

Anixa Biosciences Announces Additional Patent Issued on Cancer Detection Technology

SAN JOSE, Calif., July 24, 2019 /PRNewswire/ -- Anixa Biosciences, Inc. (NASDAQ: ANIX), a biotechnology company focused on harnessing the body's immune system to fight...

Anixa Biosciences Announces U.S. Department of Veterans Affairs VA Maryland Health Care System Joins...

SAN JOSE, Calif., July 22, 2019 /PRNewswire/ -- Anixa Biosciences, Inc. (NASDAQ: ANIX), a biotechnology company focused on harnessing the body's immune system to fight cancer,...

Anixa Update Call Full Transript

Operator:Good day, everyone. Welcome to today’s corporate update and discussion of recent alliance with Cleveland Clinic on breast cancer vaccine. At this time, all...

Anixa Licenses Another Potential Blockbuster

In January we proclaimed Anixa to be Tailwinds’ stock of the year. This designation was awarded due to potential major milestones in the both...

Anixa Biosciences Announces a Strategic Alliance and Licensing Agreement with Cleveland Clinic for an...

SAN JOSE, Calif., July 17, 2019 /PRNewswire/ -- Anixa Biosciences, Inc. (NASDAQ: ANIX), a biotechnology company focused on harnessing the body's immune system to fight cancer, today announced that...

Anixa Biosciences Highlights Recent Publication in The Journal of Experimental Medicine on Myeloid Derived...

Tailwinds' Take: This is a very technical study, but here are key points: 1. George Dominguez and Amit Kumar from Anixa are co-authors with the scientists at...

A Shallow Dive From The Deep South

In what is shaping up as a never-ending quest to provide newsletter coverage from anyplace not named "home", this week's letter comes from Raleigh,...

Three Thoughts on Anixa’s S-3

This afternoon Anixa (ANIX) filed a mixed-shelf offering of up to $100M in securities. Included in this was a sales agreement with B. Riley...

Markets Trade Down In May…June Preview

I'm not sure why, but it seems that every time I feel the Tailwinds' Portfolio is poised for big gains, the market enters a...
DFC Advisory Services LLC (dba Tailwinds Research) is a registered investment adviser. Information presented is for educational purposes only and does not intend to make an offer or solicitation for the sale or purchase of any specific securities, investments, or investment strategies. Investments involve risk and unless otherwise stated, are not guaranteed. Be sure to first consult with a qualified financial adviser and/or tax professional before implementing any strategy discussed herein. Past performance is not indicative of future performance.